IMEX   05356
INSTITUTO DE MEDICINA EXPERIMENTAL
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Cysteinyl leukotrienes levels and their receptors expression in colonic mucosa of patients with inflammatory bowel disease
Autor/es:
MORA G, ALCAIN J, ANDRUSH A, CATUOGNO P, VERMEULEN M
Lugar:
Cancún
Reunión:
Congreso; 5th LATIN AMERICAN CONGRESS OF AUTOIMMUNITY; 2017
Institución organizadora:
LACA
Resumen:
Cysteinyl leukotrienes are lipid mediators derivedfrom the metabolism of arachidonic acid.  They are potent pro-inflammatory mediators associatedwith asthma, arthritis, psoriasis, ulcerative colitis, etc. Their effects occurthrough 2 types of membrane receptors: CysLTR I and II. Objective: To evaluate the levels of LTC4 and its receptor?sexpression in colonic mucosa of patients with inflammatory bowel disease (IBD).Patients andmethods: Colon biopsies of patientswith diagnosis of IBD (OMS) were obtained through videocolonoscopy. Sampleswere analyzed with hematoxylin-eosin and semiquantitatively classified forneutrophilic recruitment. CysLTR type 1 y 2 were determined (RT-PCR), and LTC4and IL-8 (ELISA). Control group were sex and age matched patients undergoingconventional screening for colorectal cancer (OMS).  The project was approved by the institutionalethics committee.  Results: Twelve patients (6 women, 6 men) medium aged 49.75years-old were compared with 12 controls (7 women, 5 men), 50.5 years-old. Significantincrease in neutrophil percentages and IL-8 levels at the transversal colon andsigmoid rectum were found (Figure1 Ai/Aii - Bi/Bii)in patients versus controls. This correlated positively with CysLTR1 and LTC4levels (p=0.01, Fisher´s test). These findings seemed more prominent inpatients with extraintestinal manifestations (one patient with ulcerativecolitis plus psoriasis, autoimmune hepatitis and type I diabetes, and two otherpatients, one with ulcerative colitis and other with Crohn?s, both witharthritis). Conclusion: Our results may indicate that LTC4 plays a centralrole in the gut?s mucosa inflammatory response of our group of patients with IBD,and particularly in those with extra intestinal manifestations.